IBIO vs DBVT vs IMVT vs ADMA

For growth investors, iBio, Inc.

(IBIO) is the stronger pick with 77. 8% revenue growth year-over-year, versus 19. 6% for ADMA Biologics, Inc. (ADMA). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -99. 8% for iBio, Inc. (IBIO). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus IBIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ADMA Biologics, Inc.

(ADMA) is the lower-risk stock at 1. 22β versus iBio, Inc. 's 2. 03β — meaning IBIO is approximately 67% more volatile than ADMA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 24% for iBio, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), iBio, Inc.

(IBIO) is pulling ahead at 77. 8% versus 19. 6% for ADMA Biologics, Inc. (ADMA). On earnings-per-share growth, the picture is similar: iBio, Inc. grew EPS 73. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -45. 9% for iBio, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -46. 5% for IBIO. At the gross margin level — before operating expenses — IBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ADMA: 165.

6% to $22. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ADMA Biologics, Inc.

(ADMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). iBio, Inc. (IBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADMA: +39. 8%, IBIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IBIO is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.